J Korean Diabetes.  2022 Jun;23(2):77-82. 10.4093/jkd.2022.23.2.77.

Precision Medicine in Type 2 Diabetes

• Jeon E

• KMID: 2531490
• DOI: http://doi.org/10.4093/jkd.2022.23.2.77

Abstract

Precision medicine is an innovative approach to tailoring disease prevention and treatment that takes into account differences in people’s genes, environments, and lifestyle patterns. The aim of such an approach is to lead a shift in the clinical treatment paradigm from a trial-and-error or perceptive approach to the right drug, for the right patient, at the right time. The characterization of human biology and behaviors is now possible at scale owing to advances in biomarkers, bioimaging, and wearable technologies. In addition, big data from electronic medical records, health insurance databases, and other platforms have become available. These have enabled the generation of new insights into the phenotype known as diabetes. Precision medicine in diabetes (PMD) refers to an approach to optimize the diagnosis, prediction, and prevention or treatment of diabetes by integrating multi-dimensional data accounting for individual differences. The potential for precision treatment in diabetes is vast and should be considered cost-effective. Compared to precision medicine of monogenic diabetes, precision medicine of type 2 diabetes is difficult due to the polygenic condition in which environment as well as thousands of etiological genetic variants play an important role. Although there are the great concerns about PMD, which is complex and difficult to do, is required much time, we look forward to clinical utility in the treatment of patients based on their effects on different classes of markers, including race, metabolic status, other phenotypic markers, and omics data for each class of antihyperglycemic medication in the near future.

Keyword

Diabetes mellitus; Precision medicine

Figure

• 

  Fig. 1. Precision medicine in type 2 diabetes at various stages.

Reference

1.Chung WK., Erion K., Florez JC., Hattersley AT., Hivert MF., Lee CG. Precision medicine in diabetes: a Con-sensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020. 63:1671–93.

2.Nolan JJ., Kahkoska AR., Semnani-Azad Z., Hivert MF., Ji L., Mohan V. ADA/EASD Precision medicine in diabetes initiative: an international perspective and future vision for precision medicine in diabetes. Diabetes Care. 2022. 45:261–6.

3.Ahlqvist E., Storm P., Käräjämäki A., Martinell M., Dorkhan M., Carlsson A. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018. 6:361–9.

4.Udler MS. Identifying subgroups of people at risk for type 2 diabetes. Nat Med. 2021. 27:23–5.

5.Udler MS., Kim J., von Grotthuss M., Bonàs-Guarch S., Cole JB., Chiou J. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 2018. 15:e1002654.

6.Dennis JM., Shields BM., Henley WE., Jones AG., Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019. 7:442–51.

7.Angwin C., Jenkinson C., Jones A., Jennison C., Henley W., Farmer A. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. BMJ Open. 2020. 10:e042784.

8.DiCorpo D., LeClair J., Cole JB., Sarnowski C., Ahmadizar F., Bielak LF. Type 2 diabetes partitioned polygenic scores associate with disease outcomes in 454,193 indi-viduals across 13 cohorts. Diabetes Care. 2022. 45:674–83.

9.Fitipaldi H., McCarthy MI., Florez JC., Franks PW. A global overview of precision medicine in type 2 diabetes. diabetes. 2018. 67:1911–22.